Market Overview

Why Trillium's Stock Is Trading Higher Today

Share:
Why Trillium's Stock Is Trading Higher Today

Trillium Therapeutics (NASDAQ: TRIL) shares are trading higher on Thursday after HC Wainwright & Co upgraded the stock from Neutral to Buy and announced a price target of $16.60 per share.

The stock rose 40% yesterday on encouraging updated data from its ongoing lead cancer candidates TTI-622 and TTI-621.

Trillium Therapeutics Inc is a Canadian clinical stage immuno-oncology company which is engaged in developing therapies for the treatment of cancer. The lead program of the company is TTI-621 which is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal.

The company has proprietary medicinal chemistry platform, using fluorine chemistry which permits the creation of new chemical entities with pharmacological properties. The company operates through the single segment being Research and development of therapies for the treatment of cancer.

Trillium Therapeutics shares were trading up 5.22% at $14.30 on Thursday. The stock has a 52-week high of $14.94 and a 52-week low of 24 cents.

Latest Ratings for TRIL

DateFirmActionFromTo
Sep 2020HC Wainwright & Co.UpgradesNeutralBuy
Sep 2020JMP SecuritiesMaintainsMarket Outperform
Aug 2020Craig-HallumInitiates Coverage OnBuy

View More Analyst Ratings for TRIL
View the Latest Analyst Ratings

 

Related Articles (TRIL)

View Comments and Join the Discussion!

Posted-In: why it's movingUpgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
LADCraig-HallumMaintains300.0
ZGTruist SecuritiesMaintains115.0
DDOGMizuhoMaintains116.0
DISMoffettNathansonMaintains136.0
AMAGPiper SandlerUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com